Business
Cardiol Therapeutics to Participate in Upcoming Virtual Investor Conferences
Oakville, Ontario--(Newsfile Corp. - January 7, 2021) - Cardiol Therapeutics Inc. ( TSX: CRD...
About this update from Cardiol Therapeutics Inc. Class A
[{"type":"text","content":"Cardiol Therapeutics to Participate in Upcoming Virtual Investor ConferencesOakville, Ontario--(Newsfile Corp. - January 7, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (\"Cardiol\" or the \"Company\"), a clinical-stage biotechnology company focused on developing innovative therapies for inflammatory heart disease, announced today that David Elsley, President and CEO of Cardiol, will participate in the following upcoming virtual investor conferences: 10th Annual LifeSci Partners Corporate Access Event - January 6-8 and 11-14, 2021. Mr. Elsley will present, participate in a panel discussion \"Developing Drugs for Cardiovascular Indications\", and hold one-on-one investor meetings. H.C. Wainwright Bioconnect 2021 Conference - January 11-14, 2021. Mr. Elsley will give a presentation which will also be available for viewing on Cardiol's website. Biotech Showcase 2021 - January 11-15, 2021. Mr. Elsley will present and hold one-on-one investor meetings.ATB 9th Annual Institutional Investor Conference - January 13-14, 2021. Mr. Elsley will participate in a panel discussion \"Cannabinoid-derived Pharmaceuticals & Biosynthesis\" and hold one-on-one investor meetings.About Cardiol Therapeutics. Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) is a clinical-stage biotechnology company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease (\"CVD\"). The Company's lead product, CardiolRx™, is a pharmaceutically produced oral cannabidiol formulation that is currently entering a Phase II/III outcomes study in patients hospitalized for COVID-19. This trial, potentially leading to registration, is designed to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce mortality and major cardiovascular events in COVID-19 patients who have a prior history of, or risk factors for, CVD, and to investigate the effect of CardiolRx on key markers of inflammatory heart disease. Cardiol is also planning to file an IND for a Phase II international trial to investigate the anti-inflammatory and anti-fibrotic properties of CardiolRx in patients with acute myocarditis, which remains the most common cause of sudden cardiac death in people under 35 years of age. In addition, Cardiol is developing a subcutaneous formulation of CardiolR...